Abstract The world changes continuously and pharmacovigilance as a new discipline also must change. There are new fields opening with novel challenges whilst we are still perfecting ways to manage and improve the basic challenges such as inadequate data for decision making and under-reporting. Traditional medicines, vaccines, poisoning and medication error are all aspects of the safety of medicines that we have monitored for decades, though without perhaps paying enough attention to their special aspects. There are many new stakeholders taking serious interest in pharmacovigilance outside the regulatory sphere and they often focus on improving individual patient care, rather than the more traditional concentration on broad public health. The same stakeholders are also drawing attention to other iatrogenic outcomes that should be recognised, evaluated and their outcomes compared and contrasted with medication, such as harm from medical devices. The vigilance methods used for medication are very much applicable to all these new fields, though more and different expertise will be needed to evaluate outcomes.
Introduction
Modern pharmacovigilance is over 50 years old. As the first global collaborative vigilance system, the WHO Programme for International Drug Monitoring started in 1968, and has operated ever since. The Collins English Dictionary (2000) defines 'monitor' as ''A person or piece of equipment that warns, checks, controls, or keeps a continuous record of something''. Wikipedia gives a general definition of 'monitoring' as ''To be aware of the state of a system'' and may refer to ''Observe a situation for any changes which may occur over time, using a monitor or measuring device of some sort'' [1] .
It was the French who preferred the more active term 'vigilance' defined in Wikipedia as ''Alertness, the ability to maintain attention and alertness over prolonged periods of time'' [2] .
The world changes continuously and pharmacovigilance as a new discipline also changes, perhaps even faster, striving to make its mark and its voice for better patient care heard. There are new fields opening with novel challenges facing the vigilance discipline, whilst we are still perfecting ways to manage the basic situations we all recognise. Traditional medicines, vaccines, poisoning, medication error are all aspects of the safety of medicines that we have monitored for decades, though without perhaps paying enough attention to their special aspects, but new stakeholders are drawing attention to these emerging special issues [3, 4] .
New stakeholders come into the field often not knowing the history of pharmacovigilance. Their ideas must be sifted, the new and good incorporated and the duplications and irrelevancies managed. But life is more interesting than that! Pharmaceutical products are used in most branches of medicine and, in many studies of outcomes of medical care, are seen as being a cause for harm as well as good in patients, minimal for each individual medicinal product but overall causing considerable morbidity, mortality and cost to health care.
But what of other ways of managing patients: are they free of risk? They certainly are not, as shown by formal outcomes studies [5, 6] , personal experiences both direct and generalised through the media, as well as through more broadly based patient safety studies [3, 4] . Risk is present in all aspects of medical care. Those risks can range from the treatment not working right through to untimely death. The adverse outcomes may be simple, direct effects or long term, negative changes or indirect effects: they may be expected and unavoidable or unexpected but potentially avoidable.
Vigilance over healthcare outcomes is not only essential in theory, it must be practised. And pharmacovigilance is … well, vigilance! [8, 9] . The pilot project was a success [10] with several more national collaborating centres wanting to expand their work to broader issues of patient safety with medicines (predominently medication error). The WHO database (Vigibase) has allowed for categorisation of report types for many years so that it is possible to view reports from clinical studies, spontaneous reports, medication errors, different reporter types, etc., together or separately. At the same time, however, there are many stakeholders that are setting up separate programmes of reporting outcomes for vaccines, some specific for patient reports, some for medical devices, medicines that are used in specific diseases, and other outcomes of health care: outcomes research has become, rightly, popular [11] . More of them are outside the sphere of drug regulation and the WHO Programme for International Drug Monitoring, and therefore those reports, unless duplicated, do not influence global medicines regulatory activity as they should. Some examples of such websites are:
http://www.peoplespharmacy.com, http://www.patientslikeme.com, http://www.healthtalkonline.org, https://www.RxISK.org. The challenge is not only the geographic spread of data, but also the variable quality as well as the terminologies used for key fields of information. Indeed, there is an increasing amount of information in free text rather than using the standard medical terminology (MedDRA Ò ). The issues of terminologies and free text analysis are not insurmountable problems and they are already being tackled by the Uppsala Monitoring Centre (UMC) and others; for example, in the EU WEB-RADR project (http:// web-radr.eu/) that has recently commenced.
What are the other implications for reporting and learning of the diverse changes noted above? The positive side is that there is a burgeoning amount of data that relates to patient safety with medicines both within countries and internationally. It is going to be challenging to have data from many different stakeholders on the internet, but it will add richness to the discourse on pharmacovigilance.
The Challenges of Difference and Divergence
There are three major global pharmacovigilance databases that have requirements for international reporting of individual case harm reports (ICHR): the US FDA AERS (Adverse Event Reporting System) database, the EU Eudravigilance database and the WHO Vigibase. There are some differences between the data in these databases, but also many overlaps and duplications. It is possible (though it seems that accurate estimates are difficult to find) that global pharmcovigilance in Europe might cost up to €145 million [11] . Much of this will be spent on experts meeting but even if the approximately €4 million that the UMC spends on running Vigibase is considered as a standard, the cost of three very similar databases when one would provide the global data in a harmonised form to all users seems wasteful.
Moreover, the total effect of the above is duplications of data and less clinical causal analysis of the relationship between the medicine and clinical events: data quality is essential for good decisions [12] . So, not only do three databases cost more, they are potentially less efficient. Even more global databases will be expensive to set up and run but, more than that, will not allow us to compare and analyse global outcomes of therapeutic interventions for signals of possible harm.
The major challenge of such a development is the timely transfer of data from national databases to the international one. Technically, this is easily overcome but the politics and some ethical issues relating to sharing stored personal, though anonymised, data currently seem more intractable.
Quo Vadis: What Next?
Knowledge finding through data mining is now well established. In essence, the method determines how combinations of two or more data elements differ statistically significantly from a background of the remaining dataset with a relevant comparator. It is possible to evaluate how a target adverse drug reaction (ADR) with a target drug stands out against a background of the same ADR occurring as a pair with all other drugs in the dataset. One can also take a target drug, such as one vaccine and any ADR reported with it, which could be compared against the profiles of all other vaccines and ADRs looking for significant differences. It is also clearly possible to take all deaths related to a particular disease diagnosis as a pair and look for statistical disproportionalities of death plus disease diagnosis between the different therapies used.
In an automated way, disproportionality between any paired (or even multiple) data elements and the rest of the data pairs can be presented in a huge but statistically ordered list. Once the mammoth task of excluding the obvious relationships has been achieved, as well as setting a common sense (but reviewable) cut off for significance, the system can be used practically to alert anyone with appropriate domain knowledge to any new disproportional signals between any pair and the rest. This was the basis of the work done for the example in the Appendix (see electronic supplementary material).
The important factors in the success of such a venture are:
• Quality data management.
• Consistent use of defined terms for the same variables in the dataset. For example, make consistent the use of 'agranulocytosis', which may or may not mean the same as 'granulocytopenia' and avoid the use of a generic medicinal name which may cover different products with differences in effects.
• Disproportionality tools that work efficiently on large amounts of data, with the results presented in an understandable way with general caveats about interpretation.
There are a growing number of independently created, managed and structured pharmacovigilance databases, as well as large databases for other outcomes of a variety of healthcare interventions. Consequently, an increasing proportion of useful clinical outcomes data is generated that is not currently available either to the regulatory or pharmaceutical industry decision makers. This raises considerable challenges, but also the potential for creating and maintaining a coordinated network specifically created for global pooling of outcomes data.
It is well recognised that older patients may have treatments for multiple diseases. Advances in understanding and treatment of disease has also led to different modalities being used synchronously; for example, in oncology surgery, radiotherapy and chemotherapy may be used in conjunction. There is a growing realisation that safety in therapy and the management of patients is complex. Not only may the medicines interact, but the concurrent diseases may interact with the medicines (e.g. hepatic failure and medicine half-life), medicines may alter surgical outcomes (e.g. anticoagulants and bleeding/clotting), and radiotherapy may affect surgical outcomes (e.g. fibrosis negatively and tumour shrinkage positively).
On the other hand, medical (and surgical) care is increasingly compartmentalised, and each caregiver needs both information specific to that patient, as well as access to other specialised information outside their own normal knowledge/experience span. How all the patient management modalities might interact positively and negatively could be termed 'therapy (in the very broadest sense) or patient management vigilance' and it requires that information on individual outcomes needs to be captured in a coherent form, with harmonised but not standardised definitions, stored in a large database or effectively linked databases, analysed by tools that can examine risk and effectiveness as well as identifying the many factors that have influence, able to be critically scrutinised and interpreted by domain experts, and sufficient to produce useful information utilised by health professionals in all fields.
4 Final Remarks: How Could We Approach '… Vigilance'?
Since pharmacovigilance already has over 40 years of expertise in the WHO Programme for International Drug Monitoring at managing data, and has developed database structures and tools that can be adapted, why not accept all this experience with reporting individual outcomes and broaden it into other therapeutic areas? [13] This could have potentially great economic savings plus the benefits of allowing comprehensive views of the risks and benefits of therapeutic interventions overall and how they interact. The WHO has networks that are used by all areas of healthcare, and the UMC, for example, already uses a very large database with global coverage, and has tools that can manage and analyse large data fast. From early signals, hypotheses of patient harms could be corroborated by more specific methods more effectively. Within countries, the collection of large amounts of healthcare data is increasing. Pharmacovigilance centres in over 130 countries worldwide have their own national data collection processes which are harmonised to provide more than 10 million individual case report data into the WHO global network, using an agreed infrastructure to allow national centres and the network to operate.
The process of vigilance in one discipline is therefore well matured globally and also nationally in very many countries.
Conclusion
Reporting and learning for the risks and effectiveness of all kinds of therapy would be made much more efficient with coordinated data collection and analysis, bearing in mind the inter-relationships of therapeutic interventions and the need to compare outcomes of different interventions in broad effectiveness risk terms.
Interoperability of IT support systems for databases is a first essential and this is an area where there is little need to act, except to exhort the system analysts to consider the broad needs for interoperability in advance.
Much more difficult is the choice of the data fields to be collected. Often, thinking is too narrow within a project or programme: for example, childbirth registries may not have sufficiently detailed information on medication and perhaps chemical exposures during pregnancy-particularly the dates of exposure.
The terminologies used to summarise data may be different and there is a great need to consider semantic mapping (which is underway, but rather slowly), but also to move towards a global healthcare terminology structure into which terms can be fitted. It seems that the linguistics and semantics are difficult enough but whilst it is possible to relate many subsidiary terms to one at a higher level, the idea of a one-to-many relationship is too challenging.
WHO used to have the main healthcare terminology agreed globally with the WHO Family of International Classifications (WHO-FIC). This grouping included the WHO International Classification of Diseases (WHO ICD). Now, SNOMED CT (Systematized Nomenclature of Medicine-Clinical Terms) is a competing global medical terminology. Mapping of terms is feasible but is limited by the differences in granularity and architecture. It should be possible for the UN/WHO to insist on one global healthcare terminology!
The final area of difference is analyses of data. This is where expertise is required in expert understanding of the clinical contexts of use of the data. Expertise is also needed in general methodological approaches that can be used depending on the aims of the analysis, the data and the context in which it was collected, the potential for merging data, and the ability to understand the strengths and weaknesses of the result; the latter is the realm of the 'vigilance expert' and is a discipline yet to be developed.
Vigilance, therefore, is the principles of data collection, management and analysis that constitute a special discipline. Duplication for different medical domains is both wasteful of expert human resources and uneconomic. It is the expert evaluation that that needs to remain special to each clinical discipline and territory, not the data management.
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